Similarly, omecamtiv mecarbil (OM), a myosin activator with inotropic effects without altering calcium homoeostasis showed great promise (Zhou et al, 2024) but was denied FDA approval due to lack of efficacy in clinical trials. Here, MYH14 is linked to ocular melanoma.